Hemispherx Biopharma, Inc.(NYSE Amex Equities : HEB)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Loading HEB News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.78%||71.01||1.0%||$662.14m|
|ARIA||ARIAD Pharmaceuticals, Inc.||0.21%||23.75||16.4%||$442.07m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.23%||362.56||2.5%||$365.69m|
|ALXN||Alexion Pharmaceuticals, Inc.||-1.77%||131.97||2.5%||$347.73m|
|CLVS||Clovis Oncology, Inc.||2.07%||58.29||17.9%||$160.24m|
|VRTX||Vertex Pharmaceuticals Incorporated||0.57%||81.37||2.1%||$144.14m|
|IONS||Ionis Pharmaceuticals, Inc.||0.58%||46.97||8.9%||$101.63m|
|SRPT||Sarepta Therapeutics, Inc.||-4.59%||32.66||16.8%||$101.57m|
|BMRN||BioMarin Pharmaceutical Inc.||-1.78%||84.62||4.9%||$95.71m|
Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.